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he epithelial–mesenchymal interactions required for
kidney organogenesis are disrupted in mice lacking
the integrin 
 
 
 
8
 
 
 
1. None of this integrin’s known
ligands, however, appears to account for this phenotype.
To identify a more relevant ligand, a soluble integrin 
 
 
 
8
 
 
 
1
heterodimer fused to alkaline phosphatase (AP) has been
used to probe blots and cDNA libraries. In newborn mouse
kidney extracts, 
 
 
 
8
 
 
 
1-AP detects a novel ligand of 70–90
kD. This protein, named nephronectin, is an extracellular
matrix protein with ﬁve EGF-like repeats, a mucin region
containing a RGD sequence, and a COOH-terminal MAM
domain. Integrin 
 
 
 
8
 
 
 
1 and several additional RGD-bind-
ing integrins bind nephronectin. Nephronectin mRNA is
T
 
expressed in the ureteric bud epithelium, whereas 
 
 
 
8
 
 
 
1 is
expressed in the metanephric mesenchyme. Nephronectin
is localized in the extracellular matrix in the same distribu-
tion as the ligand detected by 
 
 
 
8
 
 
 
1-AP and forms a com-
plex with 
 
 
 
8
 
 
 
1 in vivo. Thus, these results strongly suggest
that nephronectin is a relevant ligand mediating 
 
 
 
8
 
 
 
1
function in the kidney. Nephronectin is expressed at nu-
merous sites outside the kidney, so it may also have wider
roles in development. The approaches used here should be
generally useful for characterizing the interactions of novel
extracellular matrix proteins identiﬁed through genomic
sequencing projects.
 
Introduction
 
Integrins are a large family of heterodimeric receptors im-
portant in development, wound healing, immunity, and ma-
lignant transformation (Hynes, 1996; Fässler et al., 1996).
The integrin 
 
 
 
8
 
 
 
1 has recently been shown to play a crucial
role during early steps of kidney morphogenesis (Müller et
al., 1997). This integrin is expressed in the metanephric
mesenchyme, but not in the ureteric bud, and is downregu-
lated as the mesenchymal cells undergo epithelialization. In
mice homozygous for a mutation in the 
 
 
 
8
 
 gene, initial
growth and branching of the ureter are severely impaired.
Thus the presence of 
 
 
 
8
 
 
 
1 promotes the development of
the ureteric bud in a non–cell-autonomous manner. Using a
soluble 
 
 
 
8
 
 
 
1 heterodimer fused to alkaline phosphatase
(AP),* we identified a potential new ligand that is colocalized
with 
 
 
 
8
 
 
 
1 at the interface between the ureter and the sur-
rounding mesenchyme (Müller et al., 1997). Fibronectin
(FN), vitronectin (VN), tenascin-C (TN-C), and osteopon-
tin (OPN) are ligands for this integrin (Müller et al., 1995;
Schnapp et al., 1995b; Varnum-Finney et al., 1995; Denda
et al., 1998b). OPN is expressed at the interface between the
ureter and the mesenchyme, and inhibition of OPN function
impairs kidney development in organ culture (Rogers et al.,
1997), but mice lacking OPN develop normal kidneys (Liaw
et al., 1998). Thus, OPN alone cannot be mediating 
 
 
 
8
 
 
 
1
function. TN-C and VN are not expressed in the correct spa-
tiotemporal pattern in the kidney to be essential ligands for
this integrin (Aufderheide et al., 1987; Seiffert et al., 1991).
Moreover, mice lacking TN-C or VN develop without kid-
ney abnormalities (Saga et al., 1992; Zheng et al., 1995).
Mice lacking FN die before the onset of kidney development
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(George et al., 1993), but FN is not expressed in the same
pattern in the embryonic kidney as the ligand detected by
 
 
 
8
 
 
 
1-AP (Ekblom, 1981; unpublished data). Thus, none of
these ligands appears to be a strong candidate to mediate the
essential functions of 
 
 
 
8
 
 
 
1 in the developing kidney.
To understand the mechanisms of 
 
 
 
8
 
 
 
1 function, we
have sought to identify a ligand that mediates its function
during kidney morphogenesis. In blots, 
 
 
 
8
 
 
 
1-AP detects
several proteins in embryonic kidney extracts, most promi-
nent of which are protein bands of 70–90 kD (Müller et al.,
1997). In this paper, we have used 
 
 
 
8
 
 
 
1-AP in an expres-
sion cloning strategy to identify novel ligands for this inte-
grin. This strategy has yielded cDNAs encoding a novel ex-
tracellular matrix protein. Its distribution indicates that it is
an extracellular matrix protein, synthesized by the ureteric
bud epithelium that is localized with 
 
 
 
8
 
 
 
1 at the interface
between the ureteric bud and the metanephric mesenchyme.
Because of its localization in the kidney extracellular matrix,
we have named it nephronectin. Nephronectin binds to in-
tegrin 
 
 
 
8
 
 
 
1 in an RGD-sensitive fashion and is the 70–90-
kD protein recognized by 
 
 
 
8
 
 
 
1-AP in protein blots. Neph-
ronectin can be coimmunoprecipitated with 
 
 
 
8
 
 
 
1 from
kidney extracts, indicating that this integrin and ligand exist
in a complex in the kidney in vivo. Based on these findings,
we suggest that nephronectin is a ligand in the kidney that
mediates 
 
 
 
8
 
 
 
1 function during development.
 
Results
 
Strategy to identify a novel ligand for integrin 
 
 
 
8
 
 
 
1
 
To identify additional ligands for the integrin 
 
 
 
8
 
 
 
1, we
used 
 
 
 
8
 
 
 
1-AP, which consists of a heterodimer of the extra-
cellular domain of 
 
 
 
8 and the extracellular domain 
 
 
 
1 fused
to AP (Fig. 1 A; Denda et al., 1998a). In previous work, this
protein complex has been shown to recognize each of the
known ligands for integrin 
 
 
 
8
 
 
 
1 and has been used success-
fully in histochemistry and protein blots (Fig. 1 B; Müller et
al., 1997; Denda et al., 1998a,b). In blots using newborn
mouse kidney extracts, 
 
 
 
8
 
 
 
1-AP recognizes a prominent
group of proteins with molecular masses between 70 and 90
kD (Fig. 1 B). At least two bands can be distinguished within
that range plus additional bands with molecular masses
 
 
 
100 kD (Fig. 1 B). Of the higher molecular mass bands,
the 200-kD band is likely to be FN (Müller et al., 1997),
whereas the other higher molecular weight bands do not
comigrate with any of the known ligands for 
 
 
 
8
 
 
 
1. Among
the known ligands for integrin 
 
 
 
8
 
 
 
1, OPN (Denda et al.,
1998b) and VN (Müller et al., 1995) are expected to comi-
grate with the 70–90-kD proteins and could be responsible
for the signals obtained in 
 
 
 
8
 
 
 
1-AP blots. VN, however, is
present in adult heart extracts (Fig. 1 D), but the 70–90-kD
bands do not show up in a blot using this tissue (Fig. 1 C). In
contrast, embryonic day 13 heart extract does not contain
any detectable VN (Fig. 1 D). Nonetheless, 
 
 
 
8
 
 
 
1-AP recog-
nizes a 70–90-kD ligand in a far Western blot of this extract
(Fig. 1 C). Similarly, kidney extracts from mice lacking OPN
show unchanged levels of the bands between 70 and 90 kD
in blots (not shown). Thus, the protein bands at 70–90-kD
and at least some of the higher molecular weight bands ap-
pear to contain additional ligands for integrin 
 
 
 
8
 
 
 
1.
To identify additional ligands for this integrin, we per-
formed an expression cloning screen using a lambda UNI-
ZAP
 
®
 
 library. The lambda phage contain inserts whose
 
expression is under the control of an isopropyl-
 
 
 
-
 
D
 
-thio-
galactopyranoside–inducible promoter and can therefore
be used to screen for expressed proteins in infected bacteria.
To select a library for this purpose, tissues for which com-
mercial UNIZAP
 
®
 
 libraries are available were screened for
the presence of 70–90-kD ligand(s) for 
 
 
 
8
 
 
 
1, using 
 
 
 
8
 
 
 
1-
AP (Fig. 1 C). Western blots of those expressing such ligands
were used to test for the presence of the FN and VN, known
 
 
 
8
 
 
 
1 ligands with molecular masses in the 70–90-kD range.
All the tissues tested contained FN (data not shown), but em-
bryonic day 13 (E13) heart was the only tissue that did not
contain detectable amounts of VN (Fig. 1 D). Thus, E13
heart was chosen as the starting tissue for the expression
screen. 2 
 
 
 
 10
 
6
 
 plaques were screened with the 
 
 
 
8
 
 
 
1-AP,
and 18 different phage were recovered. Among these, the
cDNA inserts of 15 encoded FN, whereas the other 3 en-
coded for a novel protein that we have named nephronectin,
Figure 1. Strategy to identify a novel ligand for integrin  8 1. (A) 
Schematic representation of soluble integrin  8 1-AP heterodimer. 
 8 1-AP protein was expressed as described (Denda et al., 1998a). 
The soluble  8 1-AP has the same binding characteristics as the 
transmembrane protein (Denda et al., 1998a,b). AP, secreted AP; 
His, polyhistidine tag; myc, c-myc epitope tag. (B) The soluble 
 8 1-AP recognizes several different proteins in kidney extracts. Ex-
tracts were prepared from postnatal day 0 (P0) mouse kidneys, sepa-
rated on 7% SDS-PAGE, transferred to nitrocellulose, and probed 
with  8 1-AP in the presence of 2 mM Mn
2 . The most prominent 
potential ligands for  8 1-AP have molecular masses of 70–90 kD. 
(C) Screening of mouse tissues for the presence of a 70–90-kD 
ligand(s) for  8 1-AP. Embryonic day 13 (E13) heart, adult kidney, 
and lung contain a 70–90-kD ligand(s) similar to newborn (P0) kid-
ney. (D) Embryonic day 13 heart tissue does not contain detectable 
amounts of VN, a known ligand for  8 1, as compared with other 
tissues positive for the 70–90-kD ligand. Therefore, E13 heart was 
chosen as the tissue to screen for a novel ligand for  8 1-AP.
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based on its potential role in kidney development (see be-
low). The longest cDNA of 3.4 kb contains an ORF of 1,683
bp (561 amino acids) (Fig. 2 A). The ORF extends from nu-
cleotide 124–1,810 (corresponding to 1–1,683 of the ORF)
of the 3.4-kb cDNA. The first stop codon is followed by sev-
eral stop codons in multiple reading frames that were con-
firmed by sequencing a second cDNA. The cDNA contains
an AUUAAA motif as a potential polyadenylation signal.
This is followed by a GU-rich region  25 nucleotides down-
stream from the AUUAAA site.  50 nucleotides down-
stream from the AUUAAA site is another region rich in GU.
This pattern of motifs is consistent with the overall structure
of described polyadenylation sites (Zhao et al., 1999).
A putative signal peptide is located at the NH2 terminus of
the ORF of nephronectin, suggesting that the protein is se-
creted. Nephronectin also contains five EGF–like repeats be-
tween amino acids 57–250 and a region at the COOH termi-
nus that shares homology with MAM repeats (amino acids
417–561) (Fig. 2 B). The protein also contains a RGD se-
quence at amino acids 382–384 and a potential N-glycosyla-
tion site at amino acid 273. When comparing nephronectin
to the nonredundant EMBL/GenBank/DDBJ database using
BLASTP, a protein with a similar domain organization called
EGFL6 was found (Yeung et al., 1999) (Fig. 2 C). A murine
homologue of EGFL6/MAEG has been identified (Buchner
et al., 2000). If the two proteins are aligned with the best-fit
Figure 2. Nephronectin, a novel extra-
cellular matrix protein. (A) Mouse neph-
ronectin cDNA nucleotide sequence 
and deduced amino acid sequence. The 
putative signal peptide, the EGF repeats, 
the RGD motif, N-glycosylation sites, 
and the MAM homology region are indi-
cated. (B) Alignment of the MAM do-
main. MAM domains were aligned using 
ClustalW 1.8. The boxed amino acids 
are the consensus residues of the prosite 
signature. Shaded amino acids are resi-
dues conserved in  70% of the proteins. 
(C) Overall homology of nephronectin to 
EGFL6 (Yeung et al., 1999). The two 
proteins share the same overall organi-
zation and sequence of domains. The 
least conserved domain is the one con-
taining the RGD motif.
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program, an overall sequence identity of 41% is obtained. In-
terestingly, the EGF repeat region is the most highly con-
served (60%), whereas the region between the EGF repeats
and the MAM domain is the least conserved. This region con-
tains the RGD sequence in both nephronectin and EGFL6/
MAEG (amino acids 382–384 in nephronectin, and amino
acids 362–364 in EGFL6). In nephronectin, the region from
amino acids 251–386 is encoded by a single exon (data not
shown) and is very rich in proline, serine, and threonine (62
of 131 amino acids). This is a feature found in mucin-like
proteins (Lan et al., 1990). Mucins are glycoproteins that are
highly O-glycosylated on serine and threonine residues. In-
deed, a high degree of glycosylation is predicted for this region
of nephronectin by the neural network based O-glycosylation
prediction program Net-O-glyc (http://www.cbs.dtu.dk/
services/NetOGlyc/; Hansen et al., 1998). No transmem-
brane region was detected, suggesting that nephronectin is an
extracellular matrix protein. Nephronectin also contains two
alternatively spliced exons, one encoding 17 amino acids that
is NH2-terminal to the first EGF repeat, and a second one en-
coding 31 amino acids between the first and the second EGF
repeats. All possible combinations of splice variants have been
detected by RT-PCR (data not shown). The DNA and pro-
tein sequences have been deposited in EMBL/GenBank/
DDBJ (under accession nos. AY035898 and AY035899).
Integrin  8 1 binds to nephronectin in the region 
containing an RGD sequence in an RGD-dependent manner
Integrin  8 1 is a member of the RGD-dependent subfam-
ily of integrins (Bossy et al., 1991; Schnapp et al., 1995a,b).
To test whether the binding of integrin  8 1 to nephronec-
tin is RGD sensitive, fragments of nephronectin were ex-
pressed in Escherichia coli as glutathione S-transferase (GST)
fusion proteins (Fig. 3 A). GST-neph251-561 contains the
fragment from after EGF repeat 5 to the COOH terminus
of the protein (amino acids 251–561), GST-neph251-381
from after EGF 5 to immediately before the RGD sequence
(amino acids 251–381). Both fusion proteins were expressed
in E. coli and were purified from the soluble fraction. Some
degradation was apparent. Nevertheless, strong binding of
 8 1-AP to GST-neph251-561 was observed (Fig. 3 B).
 8 1-AP binds to the intact fusion protein of  60 kD as
well as to two degradation products  50 kD and one  38
kD. This experiment also shows that integrin  8 1-AP
binds to nephronectin in the region COOH-terminal to the
EGF repeats. Most likely, the binding site includes the RGD
sequence because addition of 50  g/ml GRGDSP peptide
abolished the binding, whereas addition of the same concen-
tration of GRGESP peptide had no effect (Fig. 3 B). To ex-
plore this further, GST-neph251-381, a GST fusion protein
lacking the RGD and sequences COOH-terminal to the
Figure 3. The RGD-containing region 
in nephronectin is required for binding 
by  8 1. (A) Schematic representation 
of E. coli fusion proteins. GST-neph251-
561 contains the COOH-terminal part of 
nephronectin from immediately after the 
EGF repeats to the end of the protein, 
whereas GST-neph251-381 contains the 
fragment from the end of the EGF re-
peats to just in front of the RGD motif. 
 8 1-AP binds in an RGD-inhibitable 
manner to nephronectin. 2  g of FN, 
GST-neph251-561, or GST-neph251-
381 were separated on a 12% SDS-
PAGE, transferred to nitrocellulose, and 
probed with  8 1-AP in the presence of 
2 mM Mg
2 . (B) GRGDSP or GRGESP 
peptides were added at 50  g/ml. Note 
that, under the conditions used, binding 
of  8 1-AP to FN is weaker than to 
GST-neph251-561. This blot was devel-
oped longer than the blot in C to show 
the FN binding. Therefore, more degra-
dation products of GST-neph251-561 
are seen than in C. (C) The RGD region 
of nephronectin is required for binding 
of  8 1-AP to nephronectin. A GST fu-
sion protein lacking the RGD-containing 
region and more COOH-terminal se-
quences does not bind the  8 1-AP. (D) 
Schematic representation of fusion pro-
tein expressed in COS7 cells. Neph251-
561 contains an IgG signal peptide, a 
fragment of nephronectin extending from the COOH terminus of the EGF repeats to the end of the protein with a myc/His tag at the COOH 
terminus. SP, Ig   signal peptide; myc, myc/his tag. (E) Nephronectin fragment expressed in eukaryotic cells binds to  8 1-AP. Neph251-561 
protein was transiently expressed in COS-7 cells. Then, the supernatant was harvested and immunoprecipitated with anti-myc antibody. Im-
munoprecipitates were separated by 12% nonreducing SDS-PAGE, transferred to nitrocellulose, and probed with  8 1-AP. mock, empty 
plasmid negative control. The strong band at the top of the gel represents nonreduced 9E10 Ig.
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RGD, was used as a substrate and, as expected, did not bind
to GST-neph251-381 (Fig. 3 C). Thus, the binding site ap-
pears to be contained in amino acids 382–561 and is most
likely to include the RGD sequence, but this has not been
definitely proven by mutation of this sequence.
To determine whether improper folding, absence of disul-
fide bridges, or absence of normal glycosylation unmasks an
integrin binding site that is not present in the native protein,
the nephronectin fragment neph251-561 was transiently ex-
pressed in COS-7 cells with an NH2-terminal signal peptide
and a COOH-terminal myc/His6 tag (Fig. 3 D). Secreted
neph251-561 protein was harvested by immunoprecipitation
with anti–c-myc antibody 9E10 from conditioned medium.
It was then analyzed in blots using gels run in nonreducing
conditions (Fig. 3 E). As can be seen in Fig. 3 E,  8 1-AP
binds to this fragment of nephronectin under these condi-
tions. A single band of 60 kD is detected. The same band is
recognized by anti–c-myc antibody. Interestingly, the pre-
dicted molecular mass for neph251-561 is 41 kD. This sug-
gests the presence of a considerable amount of glycosylation,
probably in the mucin-like region of nephronectin.
Characterization of integrin interactions with nephronectin
In an effort to determine whether  8 1 and additional
RGD-binding integrins mediate attachment of cells to neph-
ronectin, we conducted adhesion assays using K562 cells ex-
pressing different integrin heterodimers. Parental K562 cells
express high levels of  5 1 and very low or undetectable lev-
els of other integrins (Blystone et al., 1994). Results in Fig. 4
A demonstrate that, even in the presence of Mn
2 , which is
an activator of all integrins, K562 cells do not bind to the
RGD-containing COOH-terminal portion of nephronectin,
neph251-561, which was purified from COS-7 cell superna-
tant. As expected, K562 cells bind efficiently in a dose-
dependent manner to FN in the presence of Mn
2 , a cat-
ion known to activate integrins. In contrast, K562 cells
expressing the  8 1 heterodimer bind efficiently to both
FN and nephronectin in dose-dependent manners. Although
amounts of the two proteins actually bound to substrata have
not be quantitated, the binding curves suggest that  8 1
binds to lower amounts of nephronectin than FN.
In studies presented later in this paper (see Fig. 9), we
have observed expression of nephronectin in numerous loca-
tions within developing embryos, suggesting that this pro-
tein may be a ligand for additional integrins. To explore this
possibility, we have examined the abilities of several K562
cell lines expressing various additional integrin heterodimers
to bind to GST-neph251-561. Results presented in Fig. 4 B
show that K562 cells expressing  8 1,   V 3,   V 5,
 V 6, and  4 7 bind strongly to this protein in the pres-
ence of Mn
2 . None of these integrins bound detectably to
GST-neph251-381 (not shown), so each could potentially
bind to the RGD sequence. In contrast, significant binding
was not observed using the parental K562 cells or K562 cells
expressing  1 1,  2 1,  3 1, or  4 1. Each cell line that
failed to bind to nephronectin was shown to bind to a char-
acterized ligand for the integrin that it expressed.  1 1- and
 2 1-expressing cells were shown to adhere efficiently to
collagen III.  3 1-expressing cells adhered efficiently to
laminin-5 (kalinin), and  4 1-expressing cells adhered to FN
in the presence of a function-blocking antibody to  5 1.
Thus, nephronectin is a ligand for several activated integrins,
including many but not all of the RGD-binding integrins
(Yang et al., 1998).
Identification of nephronectin as the 70–90-kD ligand 
for  8 1 previously identified in kidney extracts
To determine whether nephronectin is indeed the 70–90-kD
protein in kidney extracts identified as a potential novel
ligand for integrin  8 1, immunodepletions of kidney ex-
tracts were performed using an antibody prepared to the re-
combinant nephronectin fragment GST-neph251-381. The
Figure 4. Adhesion of K562 cells, and K562 expressing specific 
additional integrins, to nephronectin. (A) K562 and K562 express-
ing  8 1 were allowed to adhere to increasing concentrations, 
0.06–15.0  g/ml, of either FN or amino acids 251–561 of neph-
ronectin (NN) purified from CHO cell–conditioned medium. Experi-
ments were carried out in the presence of 1 mM Mn
2 . (B) Adhesion 
of K562 cells expressing indicated additional integrin heterodimers 
to 2  g/ml of a GST fusion protein containing amino acids 251–561 
of nephronectin in the presence of 1 mM Mn
2  and the anti- 5 mAb 
BIIG2 to inhibit  5 1-mediated adhesion. Adhesion of the parental 
K562 cells that express  5 1 to these two substrates was measured 
in the absence of the anti- 5 mAb. For all lines, OD values for wells 
coated with GST alone were subtracted. Adhesion of  8 1-express-
ing K562 cells was defined as 100% and adhesion of other cells is 
expressed as a percentage of that value.
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depleted extract and the immunoprecipitate were then ana-
lyzed by blotting (Fig. 5). In comparison to the control, vir-
tually all the 70–90-kD ligand(s) for  8 1 were lost from
the depleted extract. In addition, a 70–90-kD ligand for
 8 1 was present in the antinephronectin immunoprecipi-
tate. The same doublet of bands was also recognized by the
antinephronectin antibody in Western blots of kidney ex-
tracts (data not shown). Thus, the 70–90-kD  8 1 ligand(s)
in kidney extracts appear to mainly consist of nephronectin.
Nephronectin and  8 1 interact in the kidney in vivo
We have shown that nephronectin, a novel extracellular pro-
tein, is a ligand for  8 1 in blots and cell adhesion assays. To
determine whether nephronectin and  8 1 interact in vivo,
we examined whether they could be coimmunoprecipitated
from kidney extracts (Fig. 6). Extracts were prepared from the
kidneys of newborn mice and were immunoprecipitated with
anti–integrin  8. The immunoprecipitates were then assayed
for the presence of nephronectin using  8 1-AP (Fig. 6). In
the anti- 8 immunoprecipitate,  8 1-AP detects a doublet
of bands identical to those precipitated by antinephronectin.
This strongly suggests that integrin  8 1 and nephronectin
are associated with each other in vivo. To test the specificity
of this interaction, extracts were prepared from newborn kid-
neys in the presence of either 10 mM EDTA or GRGDSP
peptide to disrupt  8 1 integrin interactions with its ligands.
As a control for the GRGDSP peptide, the experiment was
also performed in the presence of GRGESP peptide. The in-
clusion of either EDTA or GRGDSP, but not GRGESP in
the extract and immunoprecipitation buffers greatly reduced
the presence of nephronectin in the anti– 8 immunoprecipi-
tate. Thus, the integrin  8 1 and nephronectin are associ-
ated in a complex with each other in the developing kidney.
This provides strong evidence that nephronectin is an impor-
tant functional ligand for integrin  8 1 in the kidney.
Nephronectin is expressed throughout 
kidney development
To determine whether the expression pattern of nephronec-
tin during kidney development is consistent with the possi-
bility that it is the endogenous ligand detected by  8 1-AP,
the antinephronectin antibody was first affinity purified
on the GST-neph251-561 fusion protein coupled to a
Sepharose column and was then passed over a GST–
Sepharose column to remove antibodies specific for GST
(see Materials and methods).
Nephronectin expression can be detected at E10.5 in the
urogenital ridge (Fig. 7, A and B) and at E11.5 in the Wolf-
fian and ureteric bud (Fig. 7 C, inset). At E13.5, nephronec-
tin is localized at the interface between epithelial cells of the
ureter and the surrounding metanephric mesenchyme (Fig.
7 C). Nephronectin is also localized between epithelial cells
of the ureteric bud and the surrounding mesenchyme. Ex-
pression is present at the tips of the ureter branches, but ex-
pression levels seem higher around more mature regions of
ureteric epithelia (Fig. 7, C and E). In contrast,  8 immu-
noreactivity is present in the metanephric mesenchyme (Fig.
7, D and F). In addition,  8 also is localized at the interface
between the metanephric mesenchyme and the ureteric bud
epithelium (Fig. 7 F), as would be anticipated for a receptor
to nephronectin.
The localization of nephronectin has been directly com-
pared with that of the ligand detected by  8 1-AP, and rep-
resentative results are illustrated in Fig. 7, G and H. In Fig.
Figure 5. Nephronectin is the protein(s) of 70–90 kD recognized 
by  8 1-AP in kidney extracts. Newborn mouse kidney extracts 
were immunoprecipitated with antinephronectin antiserum or pre-
immune serum. The extract, depleted extract, and the immunopre-
cipitate were analyzed in blots using  8 1-AP. Antinephronectin 
depleted virtually all  8 1-AP binding activity from the kidney ex-
tract, whereas the preimmune serum did not reduce the activity at 
70–90 kD responsible for  8 1-AP binding.
Figure 6. Coimmunoprecipitation of  8 1 with nephronectin. New-
born mouse kidney extracts were immunoprecipitated with antiintegrin 
 8 serum or antinephronectin serum in the presence or absence of 10 
mM EDTA, with 200  g/ml GRGDSP or GRGESP peptides, as indi-
cated. Precipitates were separated by 12% SDS-PAGE, were transferred 
to nitrocellulose, and were probed with  8 1-AP. The band(s) corre-
sponding to nephronectin (compare with the antinephronectin immu-
noprecipitation) are present in anti- 8 immunoprecipitates. Addition of 
EDTA leads to the disappearance of the nephronectin from the  8 im-
munoprecipitates. Inclusion of GRGDSP but not GRGESP strongly re-
duces the amount of nephronectin in the anti- 8 immunoprecipitates.
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7 G, nephronectin is visualized in a branching ureteric bud.
The distribution of the ligand detected by  8 1-AP is illus-
trated in Fig. 7 H. Comparison of the two panels indicates
that the distributions of these two ligands are very similar,
compatible with their being the same protein.
As kidney development proceeds, the mesenchyme around
the tips of the ureteric buds condenses and differentiates
into epithelial structures that later fuse with the ureteric
buds to form the proximal tubule and glomerulus of the ma-
ture kidney. Upon epithelialization of the mesenchyme, very
low levels of nephronectin expression become apparent in
comma-shaped bodies derived from the mesenchyme (Fig. 7
E). A somewhat later stage of maturation in which the epi-
thelial structure formed by condensing mesenchyme has
fused with a ureteric bud is illustrated in Fig. 7 I. Here, ex-
pression of nephronectin appears robust in the portion of
the tubule derived from the ureteric bud. Expression is low,
but significant in the S-shaped body derived from the meta-
nephric mesenchyme. At E18.5, high levels of nephronectin
are present in maturing glomeruli (Fig. 7 J).
As described above, the integrin  8 1 is expressed in the
cells of the metanephric mesenchyme. Nephronectin mRNA
was detected in RNA blots of kidney throughout meta-
nephric development (not shown). To determine which cells
express nephronectin, in situ analyses were performed using
antisense and sense cRNA probes. In analyses using the anti-
sense probe, presented in Fig. 8, A, C, and D, strong expres-
sion of mRNA encoding nephronectin is detected in tubular
epithelial cells in the E15.5 and P0 kidney. Little or no
mRNA is present in the surrounding mesenchyme. Consis-
tent with the localization of nephronectin protein, many
condensing mesenchymal structures can be observed that are
expressing very low or undetectable levels of nephronectin
mRNA. No mRNA is detected at either age using a sense
cRNA probe as a control (Fig. 8 B and not shown). A similar
but weaker pattern of expression using an antisense probe
was observed at E13.5 (not shown). Thus, nephronectin and
its receptor  8 1 appear to be synthesized by complemen-
tary cell types during kidney development.
As illustrated in Fig. 7 A, nephronectin is expressed early
during embryogenesis, before initiation of formation of the
metanephric kidney. At this stage, expression could be ob-
served under the ectoderm, in the developing urogenital sys-
tem, and in the digestive tract. Nephronectin was also
present at interfaces between differentiating somites (Fig. 7
B). As illustrated in Fig. 9, nephronectin is also present in
several organs and tissues of the embryo and neonate. At
E13.5, nephronectin is observed in the choroid plexus (Fig.
9 C) and Rathke’s pouch (Fig. 9 E). Within the embryonic
jaw, prominent expression is observed underneath the ecto-
Figure 7. Expression of nephronectin,  8 1, and the  8 1-AP 
ligand. (A and B) Expression of nephronectin in E10.5 embryo. In 
coronal section (A), prominent expression is observed in the meso-
nephric duct within the urogenital ridge and in ectoderm surrounding 
the embryo. A sagittal section (B) illustrates expression in the devel-
oping mesonephric duct. (C) Expression of nephronectin in E13.5 
kidney, as detected using antinephronectin. Note prominent expres-
sion of nephronectin at the interfaces between ureteric bud epithe-
lial cells and surrounding mesenchyme. Expression of nephronectin 
is also strong in the stalk of the ureter. An insert in lower right corner 
of C illustrates nephronectin expression in the ureteric bud at E11.5. 
(D) Expression of the integrin  8 in E13.5 kidney visualized with 
anti- 8.  8 is expressed in the mesenchyme surrounding developing 
branches of the ureteric bud.  8 also is concentrated at the interface 
between the metanephric mesenchyme and ureteric epithelial cells. 
 8 is not expressed at detectable levels in the ureteric epithelial 
cells. (E) Higher resolution pattern of expression of nephronectin in 
E13.5 kidney. Note the strong expression in the basal lamina be-
tween the ureteric bud and metanephric mesenchyme. A condens-
ing comma-shaped body of mesenchyme expresses little or no 
nephronectin. (F) Higher resolution illustration of expression of  8 
in E13.5 kidney. Note strong expression of  8 in the metanephric 
mesenchyme and the absence of expression in the ureteric bud epi-
thelial cells. (G and H) Comparison of expression patterns of neph-
ronectin (G) and the ligand-bound by  8 1-AP (H) in E13.5 kidney. 
Note that both have similar patterns of expression in branching ure-
teric buds. (I) Expression of nephronectin continues to be high in the 
ureteric bud–derived portion of a tubule created by fusion of condens-
ing mesenchyme with a ureteric bud in E13.5 kidney. Expression ap-
pears to be initiating in the S-shaped portion of this tubule derived 
from the condensing mesenchyme. (J) In the E18.5 kidney, nephronec-
tin is expressed in maturing tubules and in differentiating glomeruli. n, 
mesonephric duct; cm, condensing mesenchyme; ub, ureteric bud; st, 
ureteric stalk; c, comma-shaped body; s, S-shaped body; g, glomeru-
lus. Bars: (C and D) 250  m; (A and E–J) 100  m; (B) 50  m.
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derm and surrounding developing teeth (Fig. 9 F). Neph-
ronectin is also observed in several basal laminae in the em-
bryonic lung (Fig. 9 G), stomach, and oesophagus (Fig. 9
H). Nephronectin is also expressed by epithelial cells in the
otic system (Fig. 9 B). In neonates, expression can be ob-
served in many tissues and organs, including the lens (Fig. 9
A) and taste buds (Fig. 9 D). Expression of nephronectin ap-
pears particularly prominent at epithelial–mesenchymal in-
terfaces in tissues undergoing morphogenesis.
Discussion
In this paper, we identify and characterize a novel ligand for
the integrin  8 1. We have named this protein nephronec-
tin, because the studies that led to its discovery were initi-
ated in the developing kidney. We have shown that this pro-
tein is associated with the extracellular matrix in the kidney
where it is synthesized by ureteric epithelial cells and is de-
posited in the extracellular matrix at the interface between
these cells and the metanephric mesenchyme. The integrin
 8 1 is able to bind nephronectin in physiological salt con-
ditions and is associated with nephronectin within the de-
veloping kidney in vivo. As an endogenous ligand for this
integrin, it seems likely to be important for regulating devel-
opment of the kidney. As nephronectin is expressed in other
tissues and is recognized by other integrins, it may play a
wider role in development.
Expression cloning using soluble integrin extracellular do-
mains as probes seems likely to be generally useful for identi-
fying novel ligands for these receptors. This may be particu-
larly relevant since many constituents of the extracellular
matrix are not well characterized. For example,  4% of the
genes identified in the Drosophila genome sequencing project
are candidates for involvement in cell adhesion, and many of
these seem likely to be involved in cellular interactions with
the extracellular matrix (Hynes and Zhao, 2000). With com-
pletion of the C. elegans genome project, it has also become
clear that this organism expresses a very large number of ex-
tracellular matrix–associated molecules, many of which ap-
pear to be species specific (Hutter et al., 2000). It seems al-
most certain that the completion of vertebrate genome
sequencing projects will reveal many additional constituents
of the extracellular matrix, many of which are likely to play
important roles in organogenesis. The approach described in
this paper provides a method for identifying the proteins
present in any tissue that mediate cell adhesion. Our meth-
ods can also be used to rapidly examine the receptors capable
of binding any individual protein. As such, these procedures
should be useful in sorting out the functional properties of
the diversity of extracellular matrix proteins being identified
as part of genomic sequencing projects.
As described in the Results, examination of the EMBL/
GenBank/DDBJ database identified a homologue to neph-
ronectin named EGLF6 (human) or MAEG (mouse) (Yeung
et al., 1999; Buchner et al., 2000). The sequence of murine
nephronectin predicts an ORF of 561 amino acids including
a signal sequence of 19 amino acids, whereas that of murine
EGFL6/MAEG predicts an ORF of 550 amino acids, includ-
ing a signal sequence of 18 amino acids. In each protein the
signal sequence is followed by five EGF repeats. Interestingly,
the sequences of repeats 2, 3, and 4 in EGFL6/MAEG and of
repeats 2, 4, and 5 in nephronectin indicate that they are
Ca
2 -binding EGF domains. This subclass of EGF repeat is
found in the extracellular domains of several cell surface–asso-
ciated and extracellular matrix proteins and has been shown
to mediate protein–protein interactions (Rao et al., 1995).
Each protein also contains a MAM domain in its COOH-ter-
minal region. MAM domains have also been shown to medi-
ate protein–protein interactions, so it seems likely that neph-
ronectin and EGFL-6 interact with other proteins or with
each other in the extracellular matrix. These are the only
genes described to date that contain both Ca
2 -binding EGF
Figure 8. In situ analysis of nephronec-
tin mRNA in E15.5 and P0 kidney. 
Nephronectin mRNA is present in 
branching epithelia of the developing 
kidney at E15.5 (A) and P0 (C and D). A 
view of the P0 kidney cortex is shown in 
C. Note the many condensing mesen-
chymal structures not expressing neph-
ronectin mRNA. A view of the P0 pelvic 
region of the kidney is shown in D. Incu-
bation of sections with a sense probe as 
a control at E15.5 (B) or P1 (not shown) 
resulted in virtually no reaction product. 
Bar, 100  m.
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repeats and MAM domains (Buchner et al., 2000). In the re-
gion between the EGF repeats and the MAM domains, both
proteins have regions containing an RGD sequence as a po-
tential integrin-binding site and sequences predicted to be
modified by N-linked and O-linked glycosylation. Thus,
these two proteins share homologies in each of their domains
and may form a new subfamily of proteins. Results in this pa-
per have shown directly that nephronectin is localized to the
extracellular matrix region in the developing kidney. It seems
very likely that EGFL6/MAEG is also a constituent of the ex-
tracellular matrix. It will be surprising if it does not prove to
be a ligand for some of the RGD-binding integrins.
In previous work, the integrin  8 1 has been shown to
bind many, but not all of the RGD-containing ligands for
integrins (Müller et al., 1995; Schnapp et al., 1995b; Var-
num-Finney et al., 1995; Denda et al., 1998a,b). These
include FN, VN, OPN, and the cell-binding domain of
TN-C.  8 1, however, does not bind detectably to other
RGD-containing proteins, such as thrombospondin and en-
tactin (Denda et al., 1998a). Fibronectin has been shown
previously to be expressed in the metanephric mesenchyme
before invasion by the ureteric bud (Ekblom, 1981; Aufder-
heide et al., 1987).  8 1-AP does not exhibit detectable
binding to regions of mesenchyme not in contact with the
ureteric bud, indicating that it is not binding efficiently to
FN (Müller et al., 1997). Even though VN is a well-charac-
terized ligand for this integrin, binding to VN is not ob-
served by  8 1- P blots of adult heart, which clearly con-
Figure 9. Expression of nephronectin in 
various tissues and organs. (A) Eye of a P1 
animal. Note uniform expression of neph-
ronectin in the lens. (B) Ear of an E14.5 
embryo. Note expression of nephronectin 
in basal lamina surrounding epithelium 
and on apical surface of epithelia. (C) 
Choroid plexus of an E13.5 embryo. 
Nephronectin is localized in basal lam-
ina and is strongly expressed by epithe-
lial cells in this organ. (D) Tongue of a 
P1 animal. Nephronectin is expressed in 
developing taste buds. Lighter expres-
sion is also present in muscle. (E) 
Rathke’s pouch at E13.5. Nephronectin 
is present in the basal lamina surround-
ing this organ that develops into the pi-
tuitary gland. (F) Jaw of E13.5 animal. In 
cross section, extensive expression of 
nephronectin can be observed in the 
basal laminae underlying the skin and 
oral epithelium. Nephronectin also sur-
rounds a developing incisor (t). Lip and 
Meckel’s cartilage (mc) are indicated. 
(G) E13.5 lung. Nephronectin is ex-
pressed in the basal lamina surrounding 
the branching epithelia in this organ. In 
contrast to embryonic kidney, neph-
ronectin is also present in the surround-
ing mesenchyme. (H) Expression of 
nephronectin in various organs of E13.5 
embryo. Nephronectin expression is 
prominent in the developing stomach (s) 
and oesophagus (o). In contrast, very lit-
tle expression is present in a lobe of the 
liver (liv). Light expression is observed in 
the pancreas (p). Expression in kidney (k) 
epithelia is obvious at bottom right. Bar: 
(F) 267  m; (A and H) 200  m; (C, E, 
and G) 100  m; (B) 90  m; (D) 50  m.
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tains significant amounts of this protein as assessed using
anti-VN in Western blots (unpublished data). Thus, the
binding of this integrin to VN also appears to be less avid
than its binding to nephronectin. Expression of tenascin is
restricted to stromal cells in early stages of differentiation
(Aufderheide et al., 1987). We have not observed binding to
these cells by cytochemistry using  8 1-AP. After incuba-
tions with  8 1-AP in probes of tissue sections or blots, it is
likely that only unusually avid interactions between  8 1-
AP and its ligands are maintained during stringent washes.
Consistent with this,  8 1 and nephronectin remain associ-
ated in the presence of detergent in immunoprecipitates of
kidney extracts (Fig. 6).
Although RGD peptides have been shown to inhibit
binding to other ligands by each of the integrins shown to
bind to nephronectin in this paper (Yang et al., 1998), it is
less certain that the RGD sequence in nephronectin forms
the attachment site for each integrin. In our expression stud-
ies, the integrin binding site(s) were mapped roughly to a re-
gion of 180 amino acids that includes the RGD site. In par-
ticular, the integrin  4 sequence is not in the same subgroup
of integrin   sequences as those of  V-,  5-, and  8-, and
 4-containing integrins have been shown to bind to se-
quences not containing an RGD site (Moyano et al., 1997).
As described above, the distribution of nephronectin in
the developing kidney appears to be essentially identical to
that of the ligand(s) detected by  8 1-AP, and nephronec-
tin is clearly the major protein detected in blots of em-
bryonic kidney extracts using  8 1-AP. It is unusual for an
integrin to remain associated with its ligands after immuno-
precipitation, so the association of nephronectin with  8 1
in immunoprecipitates suggests that these two proteins are
associated in vivo. For this reason, it seems very likely to be
a critical ligand in the signaling pathway in early meta-
nephric kidney development that was revealed by the phe-
notype of mice lacking  8 1. Although this ligand is very
likely to be functionally important, we can not exclude roles
for other matrix proteins. As summarized in the Introduc-
tion, with the exception of OPN, none of the other known
ligands for  8 1 has a distribution appropriate to mediate
the essential interactions with  8 1 revealed by the  8 mu-
tant. OPN has been shown to be a ligand for  8 1 (Denda
et al., 1998b). OPN has also been shown to be localized in
the extracellular matrix between the ureteric bud epithe-
lium and metanephric mesenchyme in approximately the
same distribution as the ligand detected by  8 1-AP and
antibodies to OPN inhibit development of organ-cultured
embryonic kidneys (Rogers et al., 1997). Notably, though,
mice lacking OPN develop normal kidneys (Liaw et al.,
1998), and we have shown that these mice continue to ex-
press a ligand in the extracellular matrix between the ure-
teric bud epithelium and metanephric mesenchyme that is
detected by  8 1-AP (data not presented). These data leave
open the possibility that OPN and nephronectin have over-
lapping roles in kidney development. mRNA encoding
EGFL6/MAEG is also present in the embryonic kidney
(Buchner et al., 2000), so this protein may also help regu-
late kidney development.
The identification and characterization of nephronectin
should be useful in pursuing studies on the puzzling pheno-
type of the  8 mutant. As summarized in the Introduction,
the earliest phenotype observed in the  8 mutant is a delay
in growth of the ureteric bud into the metanephric mesen-
chyme (Müller et al., 1997). Since the integrin  8 1 is ex-
pressed in the mesenchyme and not in the ureteric bud epi-
thelium, this observation suggests that the integrin functions
in the mesenchyme to control expression or signaling effi-
ciency of a factor necessary for ureteric bud growth. During
the past few years, analyses of several mutants have identified
a growth factor–mediated signaling pathway important in
this process. Glial cell–derived neurotrophic factor (GDNF)
is synthesized in the metanephric mesenchyme (Moore et
al., 1996). Secreted GDNF has been shown to control in-
growth of the ureteric bud by binding to GFR- 1, which re-
sults in activation of the c-ret tyrosine kinase (for review see
Sariola and Sainio, 1997). The early phenotypes of mice
lacking GDNF, GFR- 1, or c-ret are very similar to that of
mice lacking the  8 1 integrin, so it seems likely that this
integrin is involved in this signaling pathway. Potentially,
nephronectin acting through  8 1 could induce a signaling
pathway that results in enhanced expression of GDNF. Al-
ternatively, it could synergize with GDNF by promoting se-
cretion of this factor or its localization in the extracellular
matrix. Whatever the mechanism, further investigations us-
ing this ligand should advance our understanding of the
puzzling function of  8 1 in kidney development.
Materials and methods
Lambda phage expression cloning
A mouse embryonic day 13 heart, Lambda UNIZAP
® library (Stratagene)
was screened with  8 1-AP as follows. Lambda phage was plated onto
15-cm NZY plates with host bacteria at a density of 50,000 plaque forming
units, as recommended by the manufacturer. Plates were incubated for 3 h
at 42 C until plaques were just visible. Nitrocellulose membranes (Strat-
agene) were wetted in 10 mM isopropyl- -D-galactopyranoside and air
dried. The membranes were placed on the plates and incubated overnight
at 30 C. Membranes were removed, washed several times with TBS (20
mM Tris/HCl, pH 7.5, 150 mM NaCl), blocked with TBS containing 3%
milk powder, probed with  8 1-AP, and developed as described above
with the addition of MnCl2. Phage were recovered from positive plaques
and rescreened until a single plaque could be picked. Excision of phage
and plasmid recovery were done as described in the Stratagene manual.
Recombinant protein production
The nephronectin fragments neph251-561 (amino acids 251–561) and
neph251-381 (amino acids 251–381) were expressed as NH2-terminal
GST fusion proteins in E. coli. Both fragments were generated by PCR and
cloned into the pGEX-4T-3 vector (Amersham Pharmacia Biotech). Con-
structs were verified by sequencing. Recombinant fusion proteins were ex-
pressed in E. coli BL21 cells. Bacteria were grown at 37 C in LB medium to
OD600   0.8 and were then transferred to 30 C. Cells were induced with 1
mM isopropyl- -D-thiogalactopyranoside and grown for an additional 2.5 h.
Cells were collected by centrifugation, resuspended in lysis buffer (50 mM
Tris-Cl, pH 8, 150 mM NaCl, 2 mM EDTA, 0.1% Triton X-100 containing
1  g/ml PMSF, 2  g/ml aprotinin, 0.7  g/ml pepstatin A), and lysed by
sonication. After centrifugation, the supernatant was incubated for 1 h at
4 C with glutathione–Sepharose (Amersham Pharmacia Biotech). Beads
were washed with lysis buffer and with PBS and eluted with PBS contain-
ing 50 mM reduced glutathione.
For expression of the nephronectin fragment neph251-561 (amino acids
251–561) in COS7 cells, a PCR fragment was generated and cloned into
the pSecTag2 vector (Invitrogen) containing an Ig   chain signal peptide
and a COOH-terminal myc/His6 tag. COS7 cells were grown in DME
(GIBCO BRL) supplemented with 10% fetal bovine serum and penicillin/
streptomycin. Cells were transiently transfected with LipofectAmine
(GIBCO BRL). After transfection, medium was changed to DME supple-
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mented with Nutridoma HU (Roche Biochemicals) and penicillin/strepto-
mycin. Conditioned medium was collected every 2 d for 8 d.
To establish stably transfected cell lines, CHO cells were transfected
with the pSecTag2-neph251-561 vector described above. 24 h after trans-
fection, 500 micrograms/ml zeocin (Invitrogen) was added to the medium.
After 2–3 wk selection, single colonies were picked and expanded. Ex-
panded clones were screened by Western blot for expression of neph251-
561. For expression of recombinant neph251-561, stably transfected CHO
cells were adapted to serum-free CHO-S-SFMII medium (GIBCO BRL) ac-
cording to the manufacturer’s instructions and grown in spinner bottles in
the presence of 250  g/ml zeocin. Conditioned medium was harvested
when cell density was  1–2 10   6 cells/ml. Cells and debris were re-
moved by centrifugation. After the addition of 0.02% sodium azide and 1
 /ml PMSF, the medium was filtered (number 1 filter; Whatman) and con-
centrated 10–20-fold using a S1Y30 spiral ultrafiltration cartridge (Ami-
con), followed by a second 10-fold concentration step through a 10-kD
cut-off ultrafiltration membrane (Amicon).
As a preclearing step, the supernatant was passed twice over a protein
G–Sepharose column (Amersham Pharmacia Biotech). The flow-through
was adsorbed to a protein G–Sepharose column coupled with anti–c-myc
antibody 9E10 (Developmental Studies Hybridoma Bank). The column
was washed with 10-column volumes PBS and eluted with 100 mM trieth-
ylamine, pH 11, washed with PBS, and eluted again with 100 mM glycine,
pH 2.5. Fractions from both elution steps containing purified nephronectin
were identified by blotting with  8 1-AP and were dialyzed against PBS.
Protein was quantified by standard protein assay (Bio-Rad Laboratories).
Recombinant   8 1-AP was expressed as described (Denda et al.,
1998a). Conditioned medium was concentrated 100-fold. Then, Tris-Cl,
pH 8, was added to a final concentration of 20 mM, and PMSF was added
to 1  g/ml. For use on blots, the conditioned medium was diluted 5–10-
fold with blocking buffer (see below).
Antibodies and reagents
An antiserum to nephronectin was generated by immunizing rabbits with
purified GST fusion protein, GST-neph251-381. For immunohistochemis-
try, the antibody was affinity purified against GST-neph251-381 coupled to
CNBr-Sepharose (Amersham Pharmacia Biotech). The antiserum was
passed over a Sepharose column coupled to GST to remove antibodies rec-
ognizing the GST. Specificity of the affinity-purified antibody was tested by
Western blot with a maltose-binding protein–nephronectin fusion protein.
Antiserum 1526 against the integrin  8 extracellular domain used in
this study has been described previously (Müller et al., 1997). Anti–mouse
VN was a gift from D. Seiffert (Seiffert, 1996). Anti–c-myc 9E10 ascites was
generated using the hybridoma cell line 9E10 developed by J.M. Bishop
and was obtained from the Developmental Studied Hybridoma Bank de-
veloped under the auspices of the National Institute of Child Health and
Human Development and maintained by The University of Iowa, Depart-
ment of Biological Sciences, Iowa City, IA 52242. Human plasma FN, the
120-kD FN fragment (FN120), bovine plasma VN, and GRGDSP and
GRGESP peptides were purchased from GIBCO BRL.
Protein extracts
Newborn mouse kidneys were homogenized in ice-cold TBS containing 1
mM PMSF, 10  g/ml leupeptin, and 0.7  g/ml pepstatin A at a 10:1 vol/wt
ratio. After centrifugation at 15,000 g in a tabletop centrifuge for 30 min,
the pellet was resuspended in extraction buffer (50 mM Tris/HCl, pH 7.5,
150 mM NaCl, 50 mM n-octylglucoside, 2 mM MgCl2, 1  g/ml PMSF, 10
 g/ml leupeptin, 0.7  g/ml pepstatin A). After a 10-min extraction, samples
were centrifuged at 15,000 rpm for 30 min to remove debris. Protein con-
centrations were determined with the detergent compatible protein assay
(Bio-Rad Laboratories), and 100  g total protein was loaded on SDS-PAGE.
Protein blots
For antigen and  8 1-AP ligand blotting, protein extracts or purified pro-
teins were boiled in SDS sample buffer, separated on 7 or 12% SDS-PAGE
and transferred to nitrocellulose membranes. Nonspecific binding sites
were blocked with blocking buffer (20 mM Tris-Cl, pH 7.5, 150 mM NaCl,
3% milk powder) at room temperature. For Western blots, the nitrocellu-
lose was incubated with antibodies diluted in blocking buffer for 1 h at
room temperature, washed three times for 5 min each with wash buffer (20
mM Tris-Cl, pH 7.5, 150 mM NaCl, 0.1% Tween-20), and incubated with
secondary antibody (goat anti–rabbit IgG, AP conjugated; Sigma-Aldrich)
for 1 h at room temperature. This was followed by three washes of 5 min
each with wash buffer and two washes with a AP buffer (100 mM Tris-Cl,
pH 9.5, 100 mM NaCl, 5 mM MgCl2). Nitrocellulose membranes were
then developed with AP buffer containing 0.33 mg/ml NBT and 0.17 mg/
ml BCIP. For blotting using  8 1-AP, blocked nitrocellulose membranes
were incubated with  8 1-AP in blocking buffer containing 2 mM MgCl2
or MnCl2 for 2 h at room temperature. Membranes were washed three
times for 5 min with TBS containing 2 mM MgCl2 or MnCl2, followed by
two washes with AP buffer. For incubations with MnCl2, 0.5 mM MnCl2
was included in the AP buffer. Blots were developed with AP buffer con-
taining 0.33 mg/ml nitro blue tetrazolium and 0.17 mg/ml 5-bromo-
4-chloro-3-indolylphosphate.
Immunohistochemistry
Histological methods were carried out as described previously (Jones et
al., 1994). Immunohistochemistry with antiintegrin  8 antiserum 1526 and
with  8 1-AP have been described previously (Müller et al., 1997; Denda
et al., 1998b). For staining with antinephronectin antibodies, sections were
blocked with 1% BSA, 0.1% Triton X-100, 1% H2O2 in PBS; washed with
1% BSA, 0.1% Triton X-100 in PBS; incubated with affinity-purified anti-
nephronectin antibody at 10  g/ml in the same buffer; washed and de-
tected with the ABC kit (Vector Laboratories); and counterstained with
Nissl as described (Jones et al., 1994).
In situ hybridization
In situ hybridization was carried out on fresh frozen sections as described
(Schaeren-Wiemers and Gerfin-Moser, 1993). For digoxygenin labeling of
probes and detection of signal, the digoxygenin RNA labeling and detec-
tion kit (Roche Biochemicals) was used. A 0.9-kb nephronectin cDNA
fragment was used as template.
Immunoprecipitation
For immunoprecipitation, antiintegrin  8 antibody was covalently coupled
to protein A–Sepharose, that was added to 500  l kidney extract for 2 h at
4 C. The beads were washed three times for 5 min with wash buffer (50
mM Tris-Cl, pH 7.5, 500 mM NaCl, 50 mM n-octylglucoside, 2 mM
MgCl2, 1  g/ml PMSF, 10  g/ml leupeptin, 0.7  g/ml pepstatin A). After
addition of SDS sample buffer, the beads were boiled for 5 min and centri-
fuged. The supernatant was collected for blot analysis.
Coimmunoprecipitations
For coimmunoprecipitations, extracts and immunoprecipitations were
done as above. As controls, 10 mM EDTA instead of MgCl2 or 600  g/ml
GRGDSP and GRGESP peptides were added to all the extraction buffers
and wash buffers in the control samples.
Cell adhesion assays
For cell adhesion assays, substrate protein was diluted in PBS to the indi-
cated concentrations. Linbro Titertek 96-well plates (Flow Laboratories)
were then treated overnight at 4 C with a total volume of 100  l of sub-
strate solution per well. The wells were blocked with 10 mg/ml BSA in PBS
for 1 h at 37 C. The cells were harvested with PBS containing 1 mM EDTA,
washed once in TBS (24 mM Tris-Cl, pH 7.4, 137 mM NaCl, 2.7 mM KCl),
counted, and then resuspended in TBS containing 0.1% BSA, 2 mM glu-
cose, 1 mM MnCl2. The cells were counted once again, and a total of
2.0   10
5 cells were plated per well. The cells were incubated for 1.5 h at
37 C, washed four times with TBS containing 1 mM MnCl2, fixed for 15
min with 2% paraformaldehyde, and stained for 5 min with 2.5% crystal
violet in 20% ethanol. Finally, each well was washed four times with wa-
ter, and adherent cells were lysed with 1% SDS. Absorption values for
each well were read at 570 nm using a microtiter plate reader and SOFT-
max v2.35 (Molecular Devices). Final absorption values for wells coated
with FN or nephronectin GST fusion proteins were determined by calculat-
ing the mean absorption value of duplicate or quadruplicate wells and
subtracting the mean value from either BSA- or GST-treated control wells
run in parallel. For antibody inhibition, cells were preincubated for 15 min
on ice with the antibody before plating. Antibody was present throughout
the adhesion assay. Antibody BIIG2 (anti- 5) was supplied as an ascites.
This ascites blocked adhesion of the parental K562 cells to FN at a dilution
of 1:20. K562 adhesion to FN was not affected by a control ascites when
used at the same concentration.
We thank Dr. Lucy Liaw (Maine Medical Center Research Institute, Scar-
borough, ME) for providing OPN mutant mice; Dr. Eric Brown (University
of California, San Francisco, San Francisco, CA) for providing K562 cells
expressing  V 3,  V 5,  V 6,  4 1, and  4 7; and Dr. Martin Hemler
(Dana Farber Cancer Institute, Boston, MA) for providing K562 cells ex-
pressing  2 1 and  3 1. We thank Dr. Caroline Damsky (University of
California, San Francisco) for anti- 5 1 mAb.
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Note added in proof: Since submision of this manuscript, Dr. Kenichi Te-
zuka and colleagues (Science University of Tokyo, Yamazaki, Noda,
Chiba, Japan) have informed us that KA8 cells (the K562 cells expressing
the integrin  8 1, used in our paper) bind to a novel protein named POEM
(preosteoblast EGF-like repeat protein with MAM domain). Dr. Tezuka and
colleagues sent us the sequence of the first 15 amino acids of POEM, and
this sequence is identical to that of the corresponding residues in neph-
ronectin. Also, POEM has the same number of EGF repeats and the same
overall structure as nephronectin. Nephronectin and POEM thus are al-
most certainly the same protein. Dr. Tezuka and colleagues have submit-
ted a manuscript on their work. 
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